Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TBCI90
- Development stage
- Preclinical
- Lead developer
- FibroGenesis
- Modality
- Cell Therapies
01
Overview
TBCI90 is a preclinical cell therapy candidate developed by FibroGenesis (formerly associated with SpinalCyte) for the treatment of cancer-related conditions, including cachexia and brain tumors. The therapy is based on a proprietary platform utilizing human dermal fibroblasts (HDFs). Specifically, TBCI90 employs "stressed" fibroblasts that are engineered to act as an immunotherapy by promoting the maturation of dendritic cells and the expansion of T cell populations. This approach aims to leverage the immunomodulatory and regenerative signaling of fibroblasts to stimulate a robust anti-tumor immune response and address systemic complications like cancer cachexia.
Beyond the preview
Go deeper on TBCI90.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TBCI90.